Mellozzan® (melatonin) launched in the UK

EQL's key product Mellozzan^® (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan^® successfully in Germany, among other countries. Unlike many other countries in Europe, there is already a growing use of melatonin to treat children with ADHD and sleep problems in the UK. The melatonin tablet market had a turnover of around £10.8 million in 2024, with a volume growth of 32% compared to 2023.

Mellozzan^® in the UK is expected to be expanded with the oral solution in 2026. The application is currently under review by the UK Medicines Agency.

About Mellozzan^®

Mellozzan^® contains the sleep hormone melatonin and is indicated for children with ADHD and sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan^® is also indicated for the short-term treatment of jet lag in adults.

About Medice

Medice Arzneimittel Pütter GmbH & Co. KG, founded in 1949 and headquartered in Iserlohn (Germany), is a fully integrated pharmaceutical company with its own GxP capabilities in the development, manufacturing and pan-European and international distribution of pharmaceuticals and medical devices. It is the core of the "Medice – The Health Family" which aims to improve patient care by offering high-quality innovative pharmaceuticals, non-pharmacological interventions and value-added services. For more information, please visit www.medice.com.